VCVeracyte VCYT · NASDAQ
$43.80 +1.58% (+$0.68)
- Market cap
- $3.52B
- Enterprise value
- $3.26B
- P/E
- 30.8x
- Forward P/E
- 23.0x
- PEG
- 0.3x
- P/S
- 6.3x
- P/FCF
- 21.3x
- EV/EBITDA
- 25.1x
- ROIC
- 7.0%
- Gross margin
- 72.1%
- Net margin
- 20.4%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -2.0x
- Beta
- 1.95
- Free float
- 99.4%
About the company
Veracyte, Inc. is an American biotechnology company specializing in diagnostics and predictive testing using advanced genomic technologies. The company develops and commercializes tests for the diagnosis and monitoring of various types of cancer and other diseases, such as lung cancer, thyroid cancer, and pulmonary fibrosis. Veracyte focuses on improving diagnostic accuracy and personalizing treatment for patients through non-invasive tests that assist healthcare providers in selecting the most appropriate therapeutic approach.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Marc Stapley
Employees
755
Headquarters
South San Francisco
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number